Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP

P J Paul1,2, D Raghu1,2, A-L Chan2

  • 1The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Oncogene
|September 20, 2016
PubMed

Insights

Targeting E3 ligase E6-associated protein (E6AP) inhibits prostate cancer (PC) growth by restoring tumor suppressor PML. Knockdown of E6AP promotes senescence and sensitizes tumors to radiation therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Restoring tumor suppressor function is a key cancer therapy strategy.
  • E3 ligase E6-associated protein (E6AP) targets the tumor suppressor promyelocytic leukemia protein (PML) for degradation.
  • The E6AP-PML interaction's role in prostate cancer (PC) is not fully understood.

Purpose of the Study:

  • To investigate the role of the E6AP-PML axis in prostate cancer progression.
  • To evaluate E6AP as a potential therapeutic target for PC.

Main Methods:

  • Knockdown (KD) of E6AP in PC cell lines and in vivo models (xenografts, patient-derived xenografts, mouse genetics).
  • Assessed PC cell growth, cellular senescence, and response to radiation.
  • Examined the impact on PML levels and tumor suppressor activity.

Main Results:

  • E6AP knockdown significantly attenuated PC cell growth in vitro and in vivo.
  • E6AP KD promoted cellular senescence and restored tumor suppressor function of PML.
  • E6AP knockdown sensitized PC cells to radiation-induced death.

Conclusions:

  • E6AP promotes prostate cancer progression.
  • Targeting E6AP is a promising therapeutic strategy for PC, potentially in combination with radiation therapy.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K